LEADER 01394nam  2200409   450 
001 9910707485003321
005 20160811094856.0
035   $a(CKB)5470000002464675
035   $a(OCoLC)956502761
035   $a(OCoLC)995470000002464675
035   $a(EXLCZ)995470000002464675
100   $a20160811d2005      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aDeficiencies in the oversight of the 340B drug pricing program
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2005.
215   $a1 online resource (v, 37 pages) $cillustration
300   $aTitle from title screen (viewed Aug. 9, 2016).
300   $a"October 2005."
300   $a"OEI-05-02-00072."
320   $aIncludes bibliographical references (pages 26-27).
517 1 $aDeficiencies in the oversight of the 340B drug pricing program
606   $aMedicaid$xAuditing
606   $aDrugs$xPrices$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aMedicaid$xAuditing.
615  0$aDrugs$xPrices
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707485003321
996   $aDeficiencies in the oversight of the 340B drug pricing program$93304891
997   $aUNINA